{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:56:43Z","timestamp":1791197803837,"version":"4.1.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002567","name":"American Academy of Allergy Asthma and Immunology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002567","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020100","name":"Mastocytosis Society Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020100","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jaci.2026.05.033","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:36:37Z","timestamp":1782776197000},"page":"1073-1084","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Selective elimination of mast cells via Siglec-6\u2013targeted nanodelivery of drug payload"],"prefix":"10.1016","volume":"158","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5418-6048","authenticated-orcid":false,"given":"Ariel Helms","family":"Thames","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton H.","family":"Rische","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Krier-Burris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie R.","family":"Klug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie R.","family":"Zelenetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan R.","family":"Burleigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle","family":"Aw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek A.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary M.","family":"Shaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swagat","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce S.","family":"Bochner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Jewett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan A.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3862-202X","authenticated-orcid":false,"given":"Jeremy A.","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2026.05.033_bib1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2340\/1651-226X.2024.31406","article-title":"Epidemiology of mastocytosis: a population-based study (Sweden)","volume":"63","author":"Bergstrom","year":"2024","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jaci.2026.05.033_bib2","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.05.033_bib3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.05.033_bib4","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","article-title":"How I treat patients with advanced systemic mastocytosis","volume":"116","author":"Valent","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.05.033_bib5","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaip.2024.12.034","article-title":"Lifetime disability-adjusted life-year assessment of indolent systemic mastocytosis","volume":"13","author":"Mounie","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.05.033_bib6","first-page":"965","article-title":"The c-kit receptor, stem cell factor, and mast cells: what each is teaching us about the others","volume":"142","author":"Galli","year":"1993","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaci.2026.05.033_bib7","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1091\/mbc.8.5.909","article-title":"c-Kit receptor signaling through its phosphatidylinositide-3\u2032-kinase-binding site and protein kinase C: role in mast cell enhancement of degranulation, adhesion, and membrane ruffling","volume":"8","author":"Vosseller","year":"1997","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.jaci.2026.05.033_bib8","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.jaci.2022.04.020","article-title":"Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: are we there yet?","volume":"149","author":"Akin","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.05.033_bib9","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1093\/annonc\/mdx290","article-title":"Midostaurin: a magic bullet that blocks mast cell expansion and activation","volume":"28","author":"Valent","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaci.2026.05.033_bib10","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1056\/NEJMc1515403","article-title":"Midostaurin in advanced systemic mastocytosis","volume":"374","author":"Chandesris","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.05.033_bib11","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/dmd.116.072744","article-title":"Midostaurin, a novel protein kinase inhibitor for the treatment of acute myelogenous leukemia: insights from human absorption, metabolism, and excretion studies of a BDDCS II drug","volume":"45","author":"He","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jaci.2026.05.033_bib12","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1182\/bloodadvances.2017011080","article-title":"Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis","volume":"2","author":"Stone","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaci.2026.05.033_bib13","article-title":"Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia","volume":"6","author":"Cerny-Reiterer","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaci.2026.05.033_bib14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40265-020-01275-2","article-title":"Avapritinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"issue":"suppl 1","key":"10.1016\/j.jaci.2026.05.033_bib15","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1182\/blood-2021-152770","article-title":"Preclinical data with KIT D816V inhibitor bezuclastinib (CGT9486) demonstrates high selectivity and minimal brain penetrance","volume":"138","author":"Guarnieri","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.05.033_bib16","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.chembiol.2019.10.008","article-title":"A highly productive, one-pot cell-free protein synthesis platform based on genomically recoded Escherichia coli","volume":"26","author":"Des Soye","year":"2019","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.jaci.2026.05.033_bib17","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1021\/acssynbio.2c00680","article-title":"Point-of-care peptide hormone production enabled by cell-free protein synthesis","volume":"12","author":"DeWinter","year":"2023","journal-title":"ACS Synth Biol"},{"key":"10.1016\/j.jaci.2026.05.033_bib18","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s10295-020-02321-4","article-title":"Cell-free systems for accelerating glycoprotein expression and biomanufacturing","volume":"47","author":"Hershewe","year":"2020","journal-title":"J Ind Microbiol Biotechnol"},{"issue":"646","key":"10.1016\/j.jaci.2026.05.033_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn1252","article-title":"Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice","volume":"14","author":"Hunt","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2026.05.033_bib20","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1038\/s41467-018-05110-x","article-title":"Single-pot glycoprotein biosynthesis using a cell-free transcription-translation system enriched with glycosylation machinery","volume":"9","author":"Jaroentomeechai","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2026.05.033_bib21","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1038\/s41467-019-12024-9","article-title":"A cell-free biosynthesis platform for modular construction of protein glycosylation pathways","volume":"10","author":"Kightlinger","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2026.05.033_bib22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1021\/acssynbio.2c00392","article-title":"A low-cost, thermostable, cell-free protein synthesis platform for on-demand production of conjugate vaccines","volume":"12","author":"Warfel","year":"2023","journal-title":"ACS Synth Biol"},{"key":"10.1016\/j.jaci.2026.05.033_bib23","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1021\/acssynbio.3c00017","article-title":"GlycoCAP: a cell-free, bacterial glycosylation platform for building clickable azido-sialoglycoproteins","volume":"12","author":"Thames","year":"2023","journal-title":"ACS Synth Biol"},{"key":"10.1016\/j.jaci.2026.05.033_bib24","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1021\/acssynbio.3c00269","article-title":"A cell-free protein synthesis platform to produce a clinically relevant allergen panel","volume":"12","author":"Thames","year":"2023","journal-title":"ACS Synth Biol"},{"key":"10.1016\/j.jaci.2026.05.033_bib25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1021\/acs.chemrev.4c00116","article-title":"Cell-free gene expression: methods and applications","volume":"125","author":"Hunt","year":"2025","journal-title":"Chem Rev"},{"key":"10.1016\/j.jaci.2026.05.033_bib26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41576-019-0186-3","article-title":"Cell-free gene expression: an expanded repertoire of applications","volume":"21","author":"Silverman","year":"2020","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jaci.2026.05.033_bib27","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5","article-title":"Click chemistry: diverse chemical function from a few good reactions","volume":"40","author":"Kolb","year":"2001","journal-title":"Angew Chem Intl Ed"},{"key":"10.1016\/j.jaci.2026.05.033_bib28","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/qsar.200740086","article-title":"Bioorthogonal click chemistry: covalent labeling in living systems","volume":"26","author":"Baskin","year":"2007","journal-title":"QSAR and Combinatorial Science"},{"key":"10.1016\/j.jaci.2026.05.033_bib29","doi-asserted-by":"crossref","first-page":"16793","DOI":"10.1073\/pnas.0707090104","article-title":"Copper-free click chemistry for dynamic in vivo imaging","volume":"104","author":"Baskin","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2026.05.033_bib30","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/s41467-018-03469-5","article-title":"Cell-free protein synthesis from genomically recoded bacteria enables multisite incorporation of noncanonical amino acids","volume":"9","author":"Martin","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2026.05.033_bib31","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1039\/C8BM01224E","article-title":"Celastrol-loaded PEG-b-PPS nanocarriers as an anti-inflammatory treatment for atherosclerosis","volume":"7","author":"Allen","year":"2019","journal-title":"Biomater Sci"},{"key":"10.1016\/j.jaci.2026.05.033_bib32","series-title":"Polymer therapeutics II","first-page":"67","article-title":"Nanostructured devices based on block copolymer assemblies for drug delivery: designing structures for enhanced drug function","author":"Nishiyama","year":"2006"},{"key":"10.1016\/j.jaci.2026.05.033_bib33","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0169-409X(00)00124-1","article-title":"Block copolymer micelles for drug delivery: design, characterization and biological significance","volume":"47","author":"Kataoka","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jaci.2026.05.033_bib34","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1021\/mp7001297","article-title":"PEG-b-PPS diblock copolymer aggregates for hydrophobic drug solubilization and release: cyclosporin A as an example","volume":"5","author":"Velluto","year":"2008","journal-title":"Mol Pharm"},{"key":"10.1016\/j.jaci.2026.05.033_bib35","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3389\/fbioe.2020.00542","article-title":"An injectable hydrogel platform for sustained delivery of anti-inflammatory nanocarriers and induction of regulatory T cells in atherosclerosis","volume":"8","author":"Yi","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.jaci.2026.05.033_bib36","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/all.15262","article-title":"Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study","volume":"77","author":"Alvarado","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.05.033_bib37","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1357-2725(99)00076-X","article-title":"The biology of stem cell factor and its receptor c-Kit","volume":"31","author":"Ashman","year":"1999","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.jaci.2026.05.033_bib38","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1096\/fj.00-0368com","article-title":"SCF\/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit","volume":"15","author":"Botchkareva","year":"2001","journal-title":"FASEB J"},{"key":"10.1016\/j.jaci.2026.05.033_bib39","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.V90.4.1345","article-title":"Stem cell factor and hematopoiesis","volume":"90","author":"Broudy","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.05.033_bib40","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/mrd.22430","article-title":"The SCF\/c-KIT system in the male: survival strategies in fertility and cancer","volume":"81","author":"Cardoso","year":"2014","journal-title":"Mol Reprod Dev"},{"key":"10.1016\/j.jaci.2026.05.033_bib41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12078-019-09277-5","article-title":"The c-kit receptor tyrosine kinase marks sweet or umami sensing T1R3 positive adult taste cells in mice","volume":"14","author":"Choo","year":"2021","journal-title":"Chemosensory Perception"},{"key":"10.1016\/j.jaci.2026.05.033_bib42","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3389\/fimmu.2019.00468","article-title":"CD117 (c-Kit) is expressed during CD8+ T cell priming and stratifies sensitivity to apoptosis according to strength of TCR engagement","volume":"10","author":"Frumento","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.05.033_bib43","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1177\/42.11.7523489","article-title":"Expression of c-kit and kit ligand proteins in normal human tissues","volume":"42","author":"Lammie","year":"1994","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.jaci.2026.05.033_bib44","doi-asserted-by":"crossref","first-page":"AB59","DOI":"10.1016\/j.jaci.2024.12.188","article-title":"Treatment with barzolvolimab improves urticaria control and quality of life in patients with chronic inducible urticaria: phase 2 12 week results","volume":"155","author":"Metz","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.05.033_bib45","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1007\/s10815-021-02181-6","article-title":"Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review","volume":"38","author":"Rambhatla","year":"2021","journal-title":"J Assist Reprod Genet"},{"key":"10.1016\/j.jaci.2026.05.033_bib46","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.3390\/cells11071138","article-title":"Functional and phenotypic characterization of Siglec-6 on human mast cells","volume":"11","author":"Robida","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jaci.2026.05.033_bib47","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jaci.2014.03.031","article-title":"Siglec-7 is an inhibitory receptor on human mast cells and basophils","volume":"134","author":"Mizrahi","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"6 pt 1","key":"10.1016\/j.jaci.2026.05.033_bib48","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1067\/mai.2000.107127","article-title":"Identification of SAF-2, a novel Siglec expressed on eosinophils, mast cells, and basophils","volume":"105","author":"Kikly","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.05.033_bib49","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s10875-011-9589-4","article-title":"Developmental, malignancy-related, and cross-species analysis of eosinophil, mast cell, and basophil Siglec-8 expression","volume":"31","author":"Hudson","year":"2011","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2026.05.033_bib50","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jaci.2023.04.007","article-title":"Siglec-9 is an inhibitory receptor on human mast cells in vitro","volume":"152","author":"Miralda","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.05.033_bib51","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/JLB.2MR0120-352RR","article-title":"Eosinophil and mast cell Siglecs: from biology to drug target","volume":"108","author":"O\u2019Sullivan","year":"2020","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jaci.2026.05.033_bib52","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","article-title":"Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial","volume":"34","author":"Amadori","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaci.2026.05.033_bib53","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.jaci.2017.06.028","article-title":"Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells","volume":"141","author":"O\u2019Sullivan","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.05.033_bib54","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1056\/NEJMoa2012047","article-title":"Anti\u2013Siglec-8 antibody for eosinophilic gastritis and duodenitis","volume":"383","author":"Dellon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.05.033_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2023.101799","article-title":"Siglecs as potential targets of therapy in human mast cell\u2013 and\/or eosinophil-associated diseases","volume":"69","author":"O\u2019Sullivan","year":"2023","journal-title":"Semin Immunol"},{"key":"10.1016\/j.jaci.2026.05.033_bib56","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1398-9995.2006.01133.x","article-title":"Alteration and acquisition of Siglecs during in vitro maturation of CD34+ progenitors into human mast cells","volume":"61","author":"Yokoi","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.05.033_bib57","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1038\/s41467-024-48678-3","article-title":"Siglec-6 as a therapeutic target for cell migration and adhesion in chronic lymphocytic leukemia","volume":"15","author":"Nunes","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2026.05.033_bib58","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/s42003-022-04207-w","article-title":"Discovery of an agonistic Siglec-6 antibody that inhibits and reduces human mast cells","volume":"5","author":"Schanin","year":"2022","journal-title":"Commun Biol"},{"key":"10.1016\/j.jaci.2026.05.033_bib59","series-title":"Allakos announces topline results from its phase 1 trial of AK006 in patients with chronic spontaneous urticaria and announces restructuring","year":"2025"},{"key":"10.1016\/j.jaci.2026.05.033_bib60","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/protein\/gzw001","article-title":"\u201cZipbody\u201d leucine zipper-fused Fab in E coli in vitro and in vivo expression systems","volume":"29","author":"Ojima-Kato","year":"2016","journal-title":"Protein Eng Des Sel"},{"key":"10.1016\/j.jaci.2026.05.033_bib61","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1038\/s41467-023-38965-w","article-title":"A rapid cell-free expression and screening platform for antibody discovery","volume":"14","author":"Hunt","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2026.05.033_bib62","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood-2013-10-534685","article-title":"A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection","volume":"124","author":"Saleh","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.05.033_bib63","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jaci.2010.12.1101","article-title":"Characterization of a novel human mast cell line that responds to stem cell factor and expresses functional FcepsilonRI","volume":"127","author":"Laidlaw","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.05.033_bib64","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/blood.V97.7.2045","article-title":"Human skin\u2013derived mast cells can proliferate while retaining their characteristic functional and protease phenotypes","volume":"97","author":"Kambe","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.05.033_bib65","series-title":"Type 2 immunity: methods and protocols","first-page":"81","article-title":"The use of human and mouse mast cell and basophil cultures to assess type 2 inflammation","author":"Caslin","year":"2018"},{"key":"10.1016\/j.jaci.2026.05.033_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.625284","article-title":"Human mast cell line HMC1 expresses functional Mas-related G-protein coupled receptor 2","volume":"12","author":"Hermans","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.05.033_bib67","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jaci.2022.07.018","article-title":"Expression and regulation of Siglec-6 (CD327) on human mast cells and basophils","volume":"151","author":"Smiljkovic","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.05.033_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20010019","article-title":"Mast Cell-Specific Expression of human Siglec-8 in conditional knock-in mice","volume":"20","author":"Wei","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2026.05.033_bib69","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jim.2005.04.016","article-title":"Affinity ranking of antibodies using flow cytometry: application in antibody phage display-based target discovery","volume":"302","author":"Geuijen","year":"2005","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jaci.2026.05.033_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.jaci.2026.05.033_bib71","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2026.05.033_bib72","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41467-018-03001-9","article-title":"Sustained micellar delivery via inducible transitions in nanostructure morphology","volume":"9","author":"Karabin","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2026.05.033_bib73","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0168-3659(03)00201-3","article-title":"Polymer vesicles in vivo: correlations with PEG molecular weight","volume":"90","author":"Photos","year":"2003","journal-title":"J Control Release"},{"key":"10.1016\/j.jaci.2026.05.033_bib74","doi-asserted-by":"crossref","first-page":"11290","DOI":"10.1021\/acsnano.6b06451","article-title":"Tailoring nanostructure morphology for enhanced targeting of dendritic cells in atherosclerosis","volume":"10","author":"Yi","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.jaci.2026.05.033_bib75","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41467-020-20886-7","article-title":"Surface chemistry\u2013mediated modulation of adsorbed albumin folding state specifies nanocarrier clearance by distinct macrophage subsets","volume":"12","author":"Vincent","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2026.05.033_bib76","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1172\/JCI138448","article-title":"Bruton\u2019s tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis","volume":"130","author":"Dispenza","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2026.05.033_bib77","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172335","article-title":"A phase II study of Bruton\u2019s tyrosine kinase inhibition for the prevention of anaphylaxis","volume":"133","author":"Suresh","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2026.05.033_bib78","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jaci.2014.11.010","article-title":"Suppression of the immunologic response to peanut during immunotherapy is often transient","volume":"135","author":"Gorelik","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.05.033_bib79","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.jaci.2015.10.009","article-title":"Chronic rhinosinusitis pathogenesis","volume":"136","author":"Stevens","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.05.033_bib80","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood.2020009192","article-title":"Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia","volume":"138","author":"Jetani","year":"2021","journal-title":"Blood"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926004458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926004458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:57:19Z","timestamp":1791194239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674926004458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0091674926004458"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2026.05.033","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective elimination of mast cells via Siglec-6\u2013targeted nanodelivery of drug payload","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2026.05.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}